Common Stock Valuation Ratios (Price Multiples)
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Current Valuation Ratios
Regeneron Pharmaceuticals Inc., current price multiples
| Regeneron Pharmaceuticals Inc. | Abbott Laboratories | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Eli Lilly & Co. | Gilead Sciences Inc. | Illumina Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Vertex Pharmaceuticals Inc. | Zoetis Inc. | Pharmaceuticals & Biotechnology | Health Care | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||
| Current share price (P) | $517.93 | |||||||||||||||||
| No. shares of common stock outstanding | 106,706,264 | |||||||||||||||||
| Growth rate (g) | 21.71% | |||||||||||||||||
| Earnings per share (EPS) | $19.83 | |||||||||||||||||
| Next year expected EPS | $24.13 | |||||||||||||||||
| Operating profit per share | $20.71 | |||||||||||||||||
| Sales per share | $73.69 | |||||||||||||||||
| Book value per share (BVPS) | $103.93 | |||||||||||||||||
| Valuation Ratios (Price Multiples) | ||||||||||||||||||
| Price to earnings (P/E) | 26.12 | 53.50 | 24.76 | 18.22 | 43.72 | 21.94 | 14.74 | 54.84 | 27.91 | 21.43 | 12.54 | 49.84 | 51.19 | 24.29 | 27.34 | |||
| Price to next year expected earnings | 21.46 | 55.70 | 19.77 | 16.00 | 45.60 | 19.05 | 11.64 | 44.39 | 33.63 | 22.18 | 11.91 | 45.37 | 36.56 | 22.22 | 24.98 | |||
| Price-earnings-growth (PEG) | 1.20 | — | 0.98 | 1.31 | — | 1.45 | 0.55 | 2.33 | — | — | 2.38 | 5.07 | 1.28 | 2.61 | 2.89 | |||
| Price to operating profit (P/OP) | 25.01 | 43.53 | 15.03 | 14.77 | 25.43 | 36.69 | 18.52 | 55.78 | 21.30 | 18.18 | 15.48 | 48.98 | 39.04 | 21.76 | 23.99 | |||
| Price to sales (P/S) | 7.03 | 6.18 | 5.87 | 6.44 | 5.75 | 8.18 | 3.59 | 15.51 | 5.14 | 4.50 | 3.94 | 14.09 | 12.27 | 5.63 | 4.48 | |||
| Price to book value (P/BV) | 4.98 | 6.35 | — | 14.77 | 2.91 | 70.00 | 3.52 | 11.91 | 7.10 | 8.14 | 3.23 | 9.64 | 28.35 | 7.19 | 6.38 | |||
Based on: 10-K (filing date: 2020-02-07).
If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.
Historical Valuation Ratios (Summary)
Regeneron Pharmaceuticals Inc., historical price multiples
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Regeneron Pharmaceuticals Inc.’s P/E ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Regeneron Pharmaceuticals Inc.’s P/OP ratio increased from 2017 to 2018 and from 2018 to 2019. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Regeneron Pharmaceuticals Inc.’s P/S ratio increased from 2017 to 2018 but then decreased significantly from 2018 to 2019. |
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Regeneron Pharmaceuticals Inc.’s P/BV ratio decreased from 2017 to 2018 and from 2018 to 2019. |
Price to Earnings (P/E)
Regeneron Pharmaceuticals Inc., historical P/E calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 110,019,809 | 109,277,189 | 107,696,798 | 106,080,755 | 104,788,145 | |
| Selected Financial Data (US$) | ||||||
| Net income (in thousands) | 2,115,800 | 2,444,400 | 1,198,511 | 895,522 | 636,056 | |
| Earnings per share (EPS)2 | 19.23 | 22.37 | 11.13 | 8.44 | 6.07 | |
| Share price1, 3 | 381.87 | 406.46 | 322.62 | 360.00 | 367.24 | |
| Valuation Ratio | ||||||
| P/E ratio4 | 19.86 | 18.17 | 28.99 | 42.64 | 60.50 | |
| Benchmarks | ||||||
| P/E Ratio, Competitors5 | ||||||
| Abbott Laboratories | 41.83 | 56.47 | 220.29 | 55.16 | 12.83 | |
| AbbVie Inc. | 17.82 | 20.60 | 35.47 | 16.54 | 17.01 | |
| Amgen Inc. | 17.07 | 14.01 | 64.06 | 16.03 | 15.95 | |
| Bristol-Myers Squibb Co. | 41.99 | 16.81 | 103.55 | 20.56 | 64.22 | |
| Eli Lilly & Co. | 16.19 | 39.13 | — | 32.39 | 33.35 | |
| Gilead Sciences Inc. | 16.45 | 15.26 | 22.75 | 6.83 | 6.75 | |
| Illumina Inc. | 43.43 | 52.00 | 44.63 | 52.01 | 50.07 | |
| Johnson & Johnson | 25.99 | 23.74 | 268.10 | 20.08 | 18.80 | |
| Merck & Co. Inc. | 20.60 | 33.46 | 61.63 | 46.14 | 31.64 | |
| Pfizer Inc. | 11.63 | 21.58 | 9.99 | 28.10 | 26.37 | |
| Vertex Pharmaceuticals Inc. | 52.90 | 22.59 | 155.08 | — | — | |
| Zoetis Inc. | 45.89 | 28.68 | 44.09 | 31.63 | 62.14 | |
| P/E Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 21.51 | 23.71 | 38.05 | 21.33 | 19.24 | |
| P/E Ratio, Industry | ||||||
| Health Care | 23.31 | 25.51 | 35.65 | 22.95 | 20.83 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Data adjusted for splits and stock dividends.
2 2019 Calculation
EPS = Net income ÷ No. shares of common stock outstanding
= 2,115,800,000 ÷ 110,019,809 = 19.23
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.
4 2019 Calculation
P/E ratio = Share price ÷ EPS
= 381.87 ÷ 19.23 = 19.86
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | Regeneron Pharmaceuticals Inc.’s P/E ratio decreased from 2017 to 2018 but then slightly increased from 2018 to 2019. |
Price to Operating Profit (P/OP)
Regeneron Pharmaceuticals Inc., historical P/OP calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 110,019,809 | 109,277,189 | 107,696,798 | 106,080,755 | 104,788,145 | |
| Selected Financial Data (US$) | ||||||
| Income from operations (in thousands) | 2,209,800 | 2,534,400 | 2,079,591 | 1,330,741 | 1,251,916 | |
| Operating profit per share2 | 20.09 | 23.19 | 19.31 | 12.54 | 11.95 | |
| Share price1, 3 | 381.87 | 406.46 | 322.62 | 360.00 | 367.24 | |
| Valuation Ratio | ||||||
| P/OP ratio4 | 19.01 | 17.53 | 16.71 | 28.70 | 30.74 | |
| Benchmarks | ||||||
| P/OP Ratio, Competitors5 | ||||||
| Abbott Laboratories | 34.03 | 36.64 | 60.88 | 24.25 | 19.80 | |
| AbbVie Inc. | 10.82 | 18.35 | 19.63 | 10.49 | 11.61 | |
| Amgen Inc. | 13.84 | 11.46 | 12.71 | 12.64 | 13.07 | |
| Bristol-Myers Squibb Co. | 24.42 | 16.16 | 28.87 | 19.79 | 53.18 | |
| Eli Lilly & Co. | 27.08 | 33.99 | 39.61 | 25.63 | 29.86 | |
| Gilead Sciences Inc. | 20.66 | 10.15 | 7.45 | 5.23 | 5.50 | |
| Illumina Inc. | 44.17 | 48.64 | 53.47 | 40.99 | 37.71 | |
| Johnson & Johnson | 19.83 | 18.34 | 18.94 | 16.09 | 16.50 | |
| Merck & Co. Inc. | 17.47 | 25.08 | 22.58 | 33.62 | 20.29 | |
| Pfizer Inc. | 14.36 | 17.19 | 15.62 | 16.88 | 15.52 | |
| Vertex Pharmaceuticals Inc. | 51.98 | 74.57 | 331.55 | 2,143.58 | — | |
| Zoetis Inc. | 35.00 | 22.59 | 22.33 | 18.65 | 28.09 | |
| P/OP Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 19.27 | 19.33 | 18.63 | 15.62 | 15.16 | |
| P/OP Ratio, Industry | ||||||
| Health Care | 20.45 | 20.05 | 19.32 | 16.43 | 15.92 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Data adjusted for splits and stock dividends.
2 2019 Calculation
Operating profit per share = Income from operations ÷ No. shares of common stock outstanding
= 2,209,800,000 ÷ 110,019,809 = 20.09
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.
4 2019 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 381.87 ÷ 20.09 = 19.01
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | Regeneron Pharmaceuticals Inc.’s P/OP ratio increased from 2017 to 2018 and from 2018 to 2019. |
Price to Sales (P/S)
Regeneron Pharmaceuticals Inc., historical P/S calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 110,019,809 | 109,277,189 | 107,696,798 | 106,080,755 | 104,788,145 | |
| Selected Financial Data (US$) | ||||||
| Revenues (in thousands) | 7,863,400 | 6,710,800 | 5,872,227 | 4,860,427 | 4,103,728 | |
| Sales per share2 | 71.47 | 61.41 | 54.53 | 45.82 | 39.16 | |
| Share price1, 3 | 381.87 | 406.46 | 322.62 | 360.00 | 367.24 | |
| Valuation Ratio | ||||||
| P/S ratio4 | 5.34 | 6.62 | 5.92 | 7.86 | 9.38 | |
| Benchmarks | ||||||
| P/S Ratio, Competitors5 | ||||||
| Abbott Laboratories | 4.83 | 4.37 | 3.84 | 3.70 | 2.78 | |
| AbbVie Inc. | 4.22 | 3.58 | 6.67 | 3.84 | 3.83 | |
| Amgen Inc. | 6.03 | 5.22 | 5.82 | 5.65 | 5.28 | |
| Bristol-Myers Squibb Co. | 5.52 | 3.67 | 5.02 | 4.72 | 6.07 | |
| Eli Lilly & Co. | 6.03 | 5.15 | 3.71 | 4.18 | 4.02 | |
| Gilead Sciences Inc. | 4.00 | 3.84 | 4.10 | 3.08 | 3.80 | |
| Illumina Inc. | 12.28 | 12.89 | 11.77 | 10.03 | 10.41 | |
| Johnson & Johnson | 4.79 | 4.45 | 4.56 | 4.62 | 4.13 | |
| Merck & Co. Inc. | 4.33 | 4.92 | 3.68 | 4.54 | 3.56 | |
| Pfizer Inc. | 3.66 | 4.49 | 4.05 | 3.84 | 3.76 | |
| Vertex Pharmaceuticals Inc. | 14.95 | 15.54 | 16.42 | 12.51 | 20.38 | |
| Zoetis Inc. | 11.00 | 7.03 | 7.18 | 5.31 | 4.42 | |
| P/S Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 4.99 | 4.70 | 4.72 | 4.40 | 4.20 | |
| P/S Ratio, Industry | ||||||
| Health Care | 3.82 | 3.57 | 3.55 | 3.23 | 3.15 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Data adjusted for splits and stock dividends.
2 2019 Calculation
Sales per share = Revenues ÷ No. shares of common stock outstanding
= 7,863,400,000 ÷ 110,019,809 = 71.47
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.
4 2019 Calculation
P/S ratio = Share price ÷ Sales per share
= 381.87 ÷ 71.47 = 5.34
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | Regeneron Pharmaceuticals Inc.’s P/S ratio increased from 2017 to 2018 but then decreased significantly from 2018 to 2019. |
Price to Book Value (P/BV)
Regeneron Pharmaceuticals Inc., historical P/BV calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 110,019,809 | 109,277,189 | 107,696,798 | 106,080,755 | 104,788,145 | |
| Selected Financial Data (US$) | ||||||
| Stockholders’ equity (in thousands) | 11,089,700 | 8,757,300 | 6,144,078 | 4,449,245 | 3,654,837 | |
| Book value per share (BVPS)2 | 100.80 | 80.14 | 57.05 | 41.94 | 34.88 | |
| Share price1, 3 | 381.87 | 406.46 | 322.62 | 360.00 | 367.24 | |
| Valuation Ratio | ||||||
| P/BV ratio4 | 3.79 | 5.07 | 5.66 | 8.58 | 10.53 | |
| Benchmarks | ||||||
| P/BV Ratio, Competitors5 | ||||||
| Abbott Laboratories | 4.96 | 4.38 | 3.40 | 3.76 | 2.68 | |
| AbbVie Inc. | — | — | 36.95 | 21.24 | 22.17 | |
| Amgen Inc. | 13.84 | 9.41 | 5.02 | 4.14 | 3.94 | |
| Bristol-Myers Squibb Co. | 2.80 | 5.89 | 8.88 | 5.66 | 7.04 | |
| Eli Lilly & Co. | 51.67 | 12.87 | 7.33 | 6.33 | 5.51 | |
| Gilead Sciences Inc. | 3.93 | 3.89 | 5.15 | 4.88 | 6.59 | |
| Illumina Inc. | 9.43 | 11.43 | 11.79 | 10.95 | 12.50 | |
| Johnson & Johnson | 6.61 | 6.08 | 5.79 | 4.72 | 4.07 | |
| Merck & Co. Inc. | 7.83 | 7.79 | 4.30 | 4.51 | 3.15 | |
| Pfizer Inc. | 3.00 | 3.80 | 2.98 | 3.40 | 2.84 | |
| Vertex Pharmaceuticals Inc. | 10.23 | 10.68 | 20.14 | 18.42 | 22.38 | |
| Zoetis Inc. | 25.42 | 18.74 | 21.52 | 17.46 | 19.72 | |
| P/BV Ratio, Sector | ||||||
| Pharmaceuticals & Biotechnology | 6.37 | 6.63 | 5.54 | 4.93 | 4.42 | |
| P/BV Ratio, Industry | ||||||
| Health Care | 5.44 | 5.42 | 4.84 | 4.32 | 3.85 | |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
1 Data adjusted for splits and stock dividends.
2 2019 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 11,089,700,000 ÷ 110,019,809 = 100.80
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.
4 2019 Calculation
P/BV ratio = Share price ÷ BVPS
= 381.87 ÷ 100.80 = 3.79
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/BV ratio | The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. | Regeneron Pharmaceuticals Inc.’s P/BV ratio decreased from 2017 to 2018 and from 2018 to 2019. |